NextSource Biotechnology, LLC announced that Gleostine® (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the United States.
Gleostine® is approved for use as a single agent treatment or in combination with other approved chemotherapeutic agents. Gleostine® is indicated to treat brain tumors—both primary and metastatic, as well as Hodgkin's disease.
"This approval adds a fourth dosage strength to the Gleostine® product line-up that now includes 5, 10, 40, and 100 mg strengths, offering physicians a wider selection of dosage options to help best tailor medical treatments to the unique needs of each patient.
This latest approval offers physicians more precise dosing options in treating patients afflicted with cancer ," said Robert DiCrisci, Founder and CEO of NextSource Biotechnology (NSB). "We believe that expanding our oncology product line will allow us to drive change in how cancer may be treated."
Subscribe to PharmaTutor News Alerts by Email >>
